SHC216V

Applied Filters:

Keyword:'SHC216V'

Showing 1-6 of 6 results for "SHC216V" within Papers

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.

Manier S

Leukemia, 31(4), 853-860 (2017)

STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.

Mesias Pedroza et al.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(1), 129-140 (2015-09-02)

Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is a key step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF-β, the

Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.

Lewis KM

Lung Cancer, 90(2), 182-190 (2015)

STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.

Pedroza M

Faseb Journal, 30(1), 129-140 (2016)

Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.

Katherine M Lewis et al.

Lung cancer (Amsterdam, Netherlands), 90(2), 182-190 (2015-09-28)

Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) has an overall 5-year survival rate of 15%. While aberrant STAT3 activation has previously been observed in NSCLC, the scope of

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Curtis A Clark et al.

Cancer research, 76(23), 6964-6974 (2016-09-28)

PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its

Page 1 of 1